Phase 3 outcomes from NEJM SURMOUNT-1, SURPASS-2, STEP-1, and Lancet Orforglipron oral GLP-1 trials—plus hepatic dawn phenomenon physiology, 15-minute post-meal GLUT4 walks, and first-30-day Type 2 Diabetes remission protocols. Explore 704 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Our results suggest that 12 weeks of exercise or metformin intervention may promote remyelination in PBT survivors in brain regions involved in memory and executive function, and there may be differences in the brain regions...
In this ITC versus semaglutide 2.4 mg, tirzepatide 10 and 15 mg were associated with statistically significant greater weight, BMI and HbA1c reduction and tirzepatide 15 mg with statistically significant improvements in...
GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently.
Semaglutide improved walking function in people with PAD and type 2 diabetes, including individuals without obesity and those with well-controlled HbA1c.
The adaptive design of the IWDAQ ensures the patient-centricity of the measure, thereby complementing existing measures of functioning in the context of weight-management clinical trials.
PYY1875 showed modest efficacy as an add-on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.
The significant changes in FBS from baseline to week 12 were - 23.1, -16.15, and - 15.25 mg/dl in the empagliflozin, sitagliptin, and metformin arm, respectively.
The current data encourages the use of semaglutide for managing WG or IWL post-bariatric surgery.
This analysis suggested greater reductions in bodyweight and HbA1c (%) levels associated with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg in people with obesity or overweight and T2D.
A significant positive linear association exists between TyG-WWI and adverse heart and blood vessel outcomes in T2DM patients, while a U-shaped relationship is observed with TM.
Shorter onset and prolonged duration of maxillary infiltration anesthesia are present in DMT2 setting.
Further research into modifiers of weight reduction phases with tirzepatide may inform treatment decisions for its use in chronic weight management.
PATIENT SUMMARY: We analyzed data from a clinical trial to evaluate the association between body mass index (BMI) and overall survival among patients with metastatic hormone-sensitive prostate cancer.
Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks...
Current literature supports tirzepatide demonstrating a higher impact on weight loss than semaglutide, with both demonstrating high rates of minimal- to moderate-severity AEs.
In Asian people with T2D suboptimally controlled on OADs or BI, iGlarLixi provided comprehensive earlier glycaemic.
This meta-analysis establishes Semaglutide as the most effective GLP-1 receptor agonist for blood sugar control and weight reduction, while Dulaglutide and Exenatide offer viable alternatives with fewer side effects.
Pioglitazone add-on therapy significantly improved glycaemic control by reducing HbA1c, fasting blood glucose and HOMA-IR while increasing the likelihood of achieving HbA1c targets.
This analysis showed that the real-world benefits and safety of finerenone in patients with CKD and T2D was not modified by baseline diuretic use.
These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
Incidence of total side effects was lower in the combination groups than in the high-intensity rosuvastatin group (p = 0.048).
We conclude that semaglutide improves blood sugar control with automated insulin delivery compared to placebo.
This study demonstrated that the FDC of DAPA + GLIM + MET ER tablets once daily was significantly better than dual FDC in achieving glycaemic control in patients with poorly controlled T2DM.
In this post hoc analysis, GI AEs appeared to contribute slightly to the weight reduction seen with tirzepatide in participants with obesity or overweight with or without T2D.
Forty-eight participants (34 [71%] female; mean [SD] age, 39.9 [10.6] years) were randomized.
Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants with type 2 diabetes.
In this post hoc analysis, tirzepatide was associated with substantial reductions in HbA1c and BW irrespective of GADA status in adults diagnosed with T2D, suggesting that tirzepatide may improve blood sugar control in...
Individuals with longer-standing T1D and low levels of C-peptide at baseline were more likely to discontinue adjunctive liraglutide treatment due to AEs/lack of tolerance than individuals with residual insulin production.
Females lost more weight than males when treated with GLP-1RAs for weight reduction.
Improvement in insulin sensitivity was proportional to weight and fat loss, with greater strength of association with tirzepatide.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
